| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8282441 | Journal of the Neurological Sciences | 2011 | 8 Pages |
Abstract
FTY720 (fingolimod) has demonstrated efficacy in multiple sclerosis (MS). We evaluated the effects of FTY720 on progressive disability, viral load, and antibody responses in mice infected with Theiler's murine encephalomyocarditis virus (TMEV). FTY720 and phosphorylated FTY720 (FTY720-P) were detected in the brain after intraperitoneal injection of the drug. Bioactivity of FTY720 was confirmed by reduced numbers of mononuclear cells in the spleen and blood after treatment. No significant differences were found in disability progression, viral load, and serum antibody responses between the FTY720-treated versus the PBS-treated mice. There was less production of IgG within the CNS in the FTY-treated group on some measures.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Libin Li, Makiko Matsumoto, Timothy J. Seabrook, Celine Cojean, Volker Brinkman, Andrew R. Pachner,